Michel van Harten, M.D., leads myTomorrows as its CEO. The company’s innovative health technology leverages a next-generation AI platform designed to accelerate and improve clinical trial recruitment. The technology directly addresses the barriers patients often face when seeking treatment options.
myTomorrows’ proprietary AI technology offers a more efficient solution than traditional methods. The platform conducts a comprehensive search of clinical trials from worldwide public registries. This enables the platform to connect patients, physicians, trial sites, and biotech companies, streamlining and speeding up access to drugs currently in development, a crucial step in modern medicine.
Dr. van Harten earned both a Bachelor of Science in Economics and his Medical Degree from the University of Amsterdam. Prior to his leadership role at myTomorrows, Dr. van Harten practiced medicine at the Antoni van Leeuwenhoek Hospital in the Department of Surgical Oncology. With over fifteen years of experience in the healthcare and pharmaceutical industries, Dr. van Harten has a strong understanding of the obstacles patients and healthcare providers encounter.
